|Dr. Michael W. Hunkapiller||Exec. Chairman, CEO & Pres||1||N/A||1949|
|Ms. Susan K. Barnes||Sr. VP & CFO||1||N/A||1954|
|Mr. James Michael Phillips||Sr. VP of R&D||393.22k||420.81k||1951|
|Ms. Kathy P. Ordoñez||Chief Commercial Officer, Exec. VP & Director||52k||N/A||1951|
|Dr. Stephen Turner Ph.D.||Co-Founder, Chief Technology Officer and VP||N/A||N/A||1968|
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 9.